Parkside Financial Bank & Trust’s TG Therapeutics TGTX Stock Holding History

Parkside Financial Bank & Trust’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.14K	Sell	130 -5	-4%	-$205	﹤0.01%	1771
2026 Q1	$4.49K	Buy	135 +17	+14%	+$507	﹤0.01%	1860
2025 Q4	$3.52K	Buy	118 +15	+15%	+$490	﹤0.01%	1907
2025 Q3	$3.72K	Sell	103 -109	-51%	-$3.59K	﹤0.01%	1818
2025 Q2	$7.63K	Buy	212 +38	+22%	+$1.42K	﹤0.01%	1575
2025 Q1	$6.86K	Buy	174 +150	+625%	+$5.05K	﹤0.01%	1541
2024 Q4	$723	Buy	24 +2	+9%	+$57	﹤0.01%	1796
2024 Q3	$515	Buy	+22	New	+$480	﹤0.01%	1830

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Parkside Financial Bank & Trust's TGTX Position: Q2 2026 in Review

Parkside Financial Bank & Trust reduced its TG Therapeutics (TGTX) stake by 3.7% in Q2 2026, selling an estimated $205 and leaving 130 shares worth $7.14K. The position accounts for ﹤0.01% of the portfolio, ranked #1771.

Parkside Financial Bank & Trust first reported a position in TGTX in Q3 2024 and has held it in 8 quarters since. The position peaked at $7.63K in Q2 2025. 430 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Parkside Financial Bank & Trust held 130 shares of TG Therapeutics worth $7.14K as of Q2 2026.
Parkside Financial Bank & Trust sold 5 TG Therapeutics shares in Q2 2026, an estimated $205.
TG Therapeutics made up ﹤0.01% of Parkside Financial Bank & Trust's portfolio in Q2 2026, its #1771 holding.
Parkside Financial Bank & Trust first reported a position in TG Therapeutics in Q3 2024 and has held it in 8 quarters since.
Parkside Financial Bank & Trust's TG Therapeutics position peaked at $7.63K in Q2 2025.
430 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Parkside Financial Bank & Trust's 13F filing for Q2 2026, filed 4 Sep 2026.